



Ching-Hsien Chen, Ph.D.

Clinical Interests

Dr. Chen has a passion for understanding and improving the treatment of cancer and fibrosis. She has established close collaborations with physician scientists to discover useful, novel biomarkers that stratify clinicopathological subtypes of solid tumors and fibrosis. These biomarkers are developed with the goal to predict treatment outcomes of patients with cancer or fibrosis undergoing clinical trials with combined inhibitors specifically targeting aberrant oncogenic signaling.

Research/Academic Interests

Dr. Chen's research interest lies in mechanism-based target identification and drug discovery in both cancer and fibrosis. Having extensive collaborations with physician scientists has allowed her to work on developing clinically relevant methods of ex-vivo expansion of primary cells. In collaboration with chemists, her team has developed a phospholipid retention approach which has yielded several useful patents and effective strategies to advance the treatment of intractable diseases.

Currently, the research foci of Dr. Chen's laboratory are 1) to discover potential therapeutic targets in both neoplastic and fibrotic diseases using integrated -omics data, genetic manipulations and pharmacological approaches; 2) to develop clinically viable methodologies for primary cell co-culture systems to study the molecular basis of cellular interaction and immune response. In addition, Dr. Chen is actively engaged in the discovery of novel therapeutics with improved or combinatorial efficacy by targeting aberrant cell signaling and metabolic pathways.

Title Associate Professor

Specialty Molecular Cancer Biology, Peptide-based Therapeutics, Functional Proteomics

Department [Internal Medicine](#)

Division Nephrology
[Pulmonary, Critical Care, and Sleep Medicine](#)

Center/Program Affiliation [UC Davis Comprehensive Cancer Center](#)

Address/Phone UC Davis Medical Center, 2315 Stockton Blvd. Sacramento, CA 95817
Phone: 800-2-UCDAVIS (800-282-3284)

Additional Phone Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Email jchchen@ucdavis.edu



Ching-Hsien Chen, Ph.D.

Languages Chinese

Education M.S., China Medical University, Taichung, Taiwan 2004
Ph.D., National Chung Hsing University, Taichung, Taiwan 2011
B.S., China Medical University, Taichung, Taiwan 2000

Fellowships Internal Medicine/Cancer, National Taiwan University, Taipei, Taiwan 2011-2012
Internal Medicine/Cancer, UC Davis, Davis CA 2012-2016

Professional Memberships American Association for Cancer Research
American Society of Nephrology
American Thoracic Society

Honors and Awards ASN Kidney Week Travel Award, The American Society of Nephrology, USA, 2016
Award for Excellence in Postdoctoral Research (Nominee), UC Davis, CA, 2015
TRDRP Postdoctoral Fellowship Award, 2014
The Department of Internal Medicine Trainee Research Award, UC Davis, CA, 2013, 2014
Phil Thai Memorial Award, 5th Annual Lung Research Symposium, UC Davis, CA, 2014

Select Recent Publications Yang DC, Chen CH. Potential New Therapeutic Approaches for Renal Cell Carcinoma. *Semin Nephrol.* 2020;40(1):86-97.

Yang DC, Xu J, Li JM, Oldham J, Phan SH, Last J, Wu R, Chen CH. Tackling MARCKS-PIP3 Circuit Attenuates Fibroblast Activation and Fibrosis Progression. *FASEB J.* 2019;33(12):14354-14369.

Xu J, Chang WH, Fong LW, Weiss RH, Yu SL, Chen CH. Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma. *Signal Transduct Target Ther.* 2019;4:2.

Chang WH, Thai P, Xu J, Yang DC, Wu R, Chen CH. Cigarette Smoke Regulates the Competitive Interactions between NRF2 and BACH1 for Heme Oxygenase-1 Induction. *Int J Mol Sci.* 2017;18(11). PMID: 29125538.

Fong LWR, Yang DC, Chen CH. Myristoylated alanine-rich C kinase substrate (MARCKS): a



Ching-Hsien Chen, Ph.D.

multirole signaling protein in cancers. *Cancer metastasis reviews*. 2017; 36(4):737-747.

Chen CH, Fong LW, Yu E, Wu R, Trott JF, Weiss RH. Up-regulation of MARCKS in kidney cancer and its potential as a therapeutic target. *Oncogene*. 2017;36(25):3588-3598.

Chen CH, Weiss RH. Getting to know ADPKD proliferative signaling, STAT. *Kidney Int*. 2017;91(3):524-526. PMID: 28202165.

Chen CH, Chang WH, Su KY, Ku WH, Chang GC, Hong QS, Hsiao YJ, Chen HC, Chen HY, Wu R, Yang PC, Chen JJW, Yu SL. HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms. *Oncogene*. 2016;35(43):5674-5685.

Chen CH, Cheng CT, Yuan Y, Zhai J, Arif M, Fong LW, Wu R and Ann DK. Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment. *Oncotarget*. 2015 20;6(17):15194-208.

Chen CH, Statt S, Chiu CL, Thai P, Arif M, Adler KB, and Wu R. Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. *Am. J. Respir. Crit. Care Medicine*. 2014; 190(10):1127-38.

To view a detailed list of Dr. Chen's publications, please [click here](#).

© 2020 UC Regents